Table 3.

Treatment-emergent adverse event reporting among patients who reported symptom bother on the OAB-S medication tolerability scale at month 1

OAB-S medication tolerability scale TEAE	Patients reporting symptom bother on the OAB-S medication tolerability scale who had reported the symptom as a TEAE, n/N (%)
	Mirabegron initiators	Antimuscarinic initiators
Dry mouth	6/86 (7.0)	4/161 (2.5)
Constipation	6/72 (8.3)	6/93 (6.5)
Headache	9/78 (11.5)	0/67 (0)
Drowsiness	2/65 (3.1)	3/67 (4.5)
Blurred vision	5/42 (11.9)	5/53 (9.4)
Nausea	1/34 (2.9)	1/38 (2.6)

OAB overactive bladder, OAB-S OAB treatment satisfaction questionnaire, TEAE treatment-emergent adverse event